Vergent Bioscience’s $21.5 Million Series B Financing

Foley Hoag LLP represented Vergent Bioscience, Inc. on the deal.Vergent Bioscience, Inc. (“Vergent”), a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced a $21.5 million Series B…